Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc.

A class action lawsuit was filed against biotechnology company Regeneron ($REGN) on July 16, which could put further pressure on its troubled share...

Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The Phase 2 study A Phase 2, Randomized, Placebo-Controlled ...

Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside

U.S. stocks ended another positive week near record highs, although Friday’s weak retail sales report took some of the shine off the rally. The S&P...

The Week That Was, The Week Ahead: Macro and Markets, August 16

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a late-stage study on n...

Regeneron Targets Cat Allergy Eye Relief With New Phase 3 Antibody Trial

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The phase 1/2 study titled “REGN15505 Alone or in Combinatio...

Regeneron Targets Next‑Gen Cancer Immunotherapy With New Phase 1/2 Trial

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Regeneron, with a price target of $917.00. According to TipRanks,...

Barclays Keeps Their Buy Rating on Regeneron (REGN)

Truist Financial analyst Gregory Renza maintained a Buy rating on Regeneron today and set a price target of $772.00. Renza covers the Healthcare se...

Truist Financial Remains a Buy on Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a new Phase 4 study in ...

Regeneron Targets Safer Outpatient Myeloma Care With New Linvoseltamab Study

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing a federal securities lawsuit alleging that investors were not fully informed about risks t...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$828.50	-0.66%	671.97K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$828.50	-0.7%	671.97K
3
4
5
6

REGN

Get Regeneron Pharmaceuticals, Inc. Data in Excel

Get Regeneron Pharmaceuticals, Inc. Data in Excel